Ptc Therapeutics (PTCT) Non-Current Deferred Tax Liability (2018 - 2024)

Ptc Therapeutics' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $55.9 million for Q3 2024.

• In Q3 2024, Non-Current Deferred Tax Liability rose 7.67% year-over-year to $55.9 million; the TTM figure through Sep 2024 stood at $55.9 million (up 7.67% YoY), while the FY2023 annual figure was $55.9 million, down 45.64% from the prior year.
• Non-Current Deferred Tax Liability for Q3 2024 stood at $55.9 million, roughly flat from $55.9 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $137.1 million in Q4 2021, with the low at $51.9 million in Q3 2023.
• The 5-year median for Non-Current Deferred Tax Liability is $130.9 million (2020), against an average of $106.4 million.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability slumped 62.13% in 2023, then advanced 7.67% in 2024.
• Ptc Therapeutics' Non-Current Deferred Tax Liability stood at $136.7 million in 2020, then advanced by 0.27% to $137.1 million in 2021, then decreased by 25.0% to $102.8 million in 2022, then tumbled by 45.64% to $55.9 million in 2023, then advanced by 0.01% to $55.9 million in 2024.
• Business Quant data shows PTCT's Non-Current Deferred Tax Liability at $55.9 million in Q3 2024, $55.9 million in Q2 2024, and $55.9 million in Q1 2024.